165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial

Rupert Bartsch, Matthias Preusser, Julia Furtner et al.|Annals of Oncology|2022

Cited by 17